A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
NCT ID: NCT00592111
Last Updated: 2015-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
21 participants
INTERVENTIONAL
1996-03-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
COPP/ABV
4 courses of COPP/ABV hybrid
2
COPP/ABV
6 courses of COPP/ABV hybrid
3
intensive chemo with concurrent growth factor
6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COPP/ABV
4 courses of COPP/ABV hybrid
COPP/ABV
6 courses of COPP/ABV hybrid
intensive chemo with concurrent growth factor
6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previously untreated, pathologically confirmed diagnosis of Hodgkin's disease.
* Informed patient/parental consent as required by individual institution and in accordance with the Dept of Health and Human Services
* Approval of this protocol by the individual institutional Human Subjects Review Committee.
* Indicate Hodgkin's disease clinical stage.
* Indicate presence or absence of "B" symptoms.
* For Stage I and II disease indicate the following:
* presence or absence of bulk disease
* number of involved nodal regions
* presence or absence of hilar adenopathy
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Cancer Group
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tanya Trippett, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCG 5942
Identifier Type: -
Identifier Source: secondary_id
CA42764
Identifier Type: -
Identifier Source: secondary_id
96-016
Identifier Type: -
Identifier Source: org_study_id